A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
51actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-05 | actual | When the study began enrolling |
| Primary completion | 2026-05-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: INCB123667
- Drug: itraconazole
- Drug: carbamazepine
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics Parameter (PK): Cmax of INCB123667
measured Up to Day 16
Pharmacokinetics Parameter: Tmax of INCB123667
measured Up to Day 16
Pharmacokinetics Parameter: AUCt of INCB123667
measured Up to Day 16
Pharmacokinetics Parameter: AUC∞ of INCB123667
measured Up to Day 16
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed